DocWire News Editors

DocwireNews

A study aimed to assess the efficacy and safety of three venetoclax (V) plus CD20 antibody-based regimens in comparison to chemoimmunotherapy (CIT) as a frontline treatment for fit patients with chronic lymphocytic leukemia (CLL) and without&nbsp;TP53&nbsp;mutation/deletion. The findings were presented by Barbara Eichhorst, MD, and colleagues at the 2021 American Society of Hematology Annual Meeting.In this trial, called GAIA, researchers analyzed a total of 926 treatment na&iuml;ve fit CLL patients (median age = 61 years) requiring therapy. Patients with&nbsp;TP53&nbsp;aberrations were excluded from analysis.The population of interest were randomized 1:1:1:1 to receive:<ul>
<li>six courses of&nbsp;CIT&nbsp;(FCR for patients &le;65 years: fludarabine 25 mg/m&sup2; days 1-3, cyclophosphamide 250 mg/m&sup2; days 1-3, rituximab 375 mg/m&sup2; day 1 cycle 1 and 500 mg/m&sup2; day 1 cycle 2-6; bendamustine-rituximab for patients &gt;65 years [bendamustine 90mg/m&sup2; days 1-2])</li>
<li>one of three&nbsp;V-based combinations
<ul>
<li>RVe: V&nbsp;and rituximab (375/500 mg/m&sup2; day 1 cycle 1-6)</li>
<li>GVe:&nbsp;V&nbsp;and obinutuzumab (1,000 mg day 1, 8, 15 cycle 1 and day 1 cycle 2-6)</li>
<li>GIVe: V, obinutuzumab, and ibrutinib (420 mg/day cycle 1-12, if measurable residual disease [MRD]-detectable continued until cycle 36)</li>
</ul>
</li>
</ul>The key outcomes of interest were defined as the rate of undetectable MRD by flow cytometry in peripheral blood (PB) at month 15, and progression-free survival (PFS), each with a significance level of 2.5%.According to the results, the endpoint of undetectable MRD in PB at 15 months was met, and the researchers noted that the rate of undetectable MRD in the intent-to-treat population was significantly higher in GVe compared to CIT: 86.5% versus 52.0% (p &lt; 0.0001), respectively. Moreover, the researchers observed that GIVe demonstrated a superior undetectable MRD rate (92.2%) compared to CIT (p &lt; 0.0001), while RVe (57.0%) did not (p = 0.317).&ldquo;The time-limited therapies of GVe and GIVe provided superior undetectable MRD rates in PB at month 15 compared to CIT. In addition, undetectable MRD rates in BM were higher in GVe and GIVe in particular than in CIT,&rdquo; the researchers concluded. They added that all study arms displayed a favorable safety profile.

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Jordana Jampel

Glycan-Targeting Novel Vaccine Shows Promise for Vast Virus Protection

Infectious Disease

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Latest News

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments Versus Standard Therapy in Frontline CLL

ASH Annual Meeting and Exposition 2021

A study aimed to assess the efficacy and safety of three venetoclax (V) plus CD20 antibody-based regimens in comparison to chemoimmunotherapy (CIT) as a frontline treatment ...

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments Versus Standard

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe